The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Facilitating Debate, Fostering Innovation,
Accelerating Access to the Best Treatments
for All Cancer Patients

 

Cancer Drug Development Forum (CDDF) is a neutral, non–competitive platform

for multi-stakeholder discussions and collaboration in the development of cancer drugs.

 

Unique Multi-Stakeholder Platform

Patients are the cornerstone of CDDF’s mission and central to our multi-stakeholder discussions. Patients and advocacy groups are invited to join the CDDF multi-stakeholder community and make their voices heard. Check out collaborative opportunities and grants available to patients.

The CDDF provides the healthcare industry with unique opportunities to collaborate with diverse stakeholders and take part in open dialogue to accelerate oncology drug development. Discover the CDDF Industry Membership Program and engage with key experts in oncology.

The CDDF fosters advancement and innovation in cancer research by creating a collaborative platform for academics to share knowledge and expertise with a multi-stakeholder audience. Join CDDF’s discussions on the latest developments and explore opportunities to contribute.

The CDDF convenes discussions on key topics in oncology, fostering a balanced exchange of perspectives. Regulators and HTA agencies can gain valuable insights and stay informed on emerging trends through our productive dialogue. Explore collaboration opportunities and join our community.

CANCER DRUG DEVELOPMENT FORUM

The leading non-competitive platform stimulating dialogue and innovation to accelerate access to effective treatments for all cancer patients.

Multi-stakeholder Interview: Get an Inside Look at the CDDF Workshop on HTA in Cancer Drug Development

We are excited to share interview clips featuring a diverse group of stakeholders at CDDF & EORTC Joint Workshop on HTA in Cancer Drug Development. Held in Brussels on 5-6 October 2026, the meeting highlighted multi-stakeholder collaboration as the cornerstone of...

🔔 [Executive Summary Published: CDDF & EORTC Joint Workshop on HTA in Cancer Drug Development]

We are delighted to announce that the executive summary of the CDDF & EORTC joint workshop on "Health Technology Assessment in Cancer Drug Development" has been published today. This multi-stakeholder workshop was held on 5-6 October 2026 in Brussels (BE) to help...

CDDF NEW WHITEPAPER: Improving Patient Access to New Treatment Modalities in European Cancer Care

We are delighted to announce that CDDF’s new whitepaper, Improving Patient Access to New Treatment Modalities in European Cancer Care, has been published in the Journal of Market Access & Health Policy this month. This paper highlights practical challenges and...

Celebrating 25 Years of the Cancer Drug Development Forum (CDDF)

  This month, CDDF marks 25 years of turning hope into...

Call for Case Studies & Panelists/Session Chairs: Upcoming ACT-EU Workshop on Multiplicity in Confirmatory Two-Arm and Platform Trials

Following a recent MSP AG discussion, stakeholders are invited to contribute for the upcoming ACT-EU workshop on multiplicity in confirmatory two-arm and platform trials, taking place on 27 November 2026 at the EMA in Amsterdam. 🔍 How you can contribute: 1️⃣ Present a...

CDDF & WECAN Foundation: Memorandum of Understanding

🔔 📢 We are delighted to announce that CDDF and the WECAN Foundation (Workgroup of European Cancer Patient Advocacy Networks) have formalized our long-standing collaboration through a Memorandum of Understanding. This partnership will enable the organizations to work...

[🔔 📊 Participate in the ENCePP Survey on AI in Pharmacoepidemiology & Pharmacovigilance]

The ENCePP Working Group on Artificial Intelligence in Pharmacoepidemiology and Pharmacovigilance invite stakeholders to contribute to a survey examining the perception and use of artificial intelligence (AI) tools across Pharmacoepidemiology (PE) and...

📢 🔔 [News from EMA – Public Consultation on Its Draft Recommendations]

The European Network of Paediatric Research at the EMA (EnprEMA) has launched a public consultation on its draft recommendations: "Cross-border access to paediatric clinical trials in Europe: preventing language exclusion." 📄 About the draft recommendations The draft...

🔔 Meeting of Interest in Cancer Drug Development: 2026 AAADV Workshop

Registration is NOW OPEN for the 2026 AAADV Workshop! 📅 Date: November 5–6, 2026 📍 Location: North Bethesda Marriott Hotel & Conference Center (In-Person & Virtual Participation Available) 📝 View the draft program: https://aaadv.org/2026-aaadv-workshop-agenda/...

ACT EU Multi-Stakeholder Platform: Meeting Documents from 18 June 2026

The meeting documents from ACT-EU MSP meeting held on 18 June 2026 are available now on the ACT EU website. These include presentations from the European Commission on Progress with the BioTech Act and specifically its clinical trial related aspects - present by C....

CDDF Webinar: AI and Big Data AI in Drug Development: Transparency and Risk Assessment (June 2026)

The recording of the recent CDDF webinar on “AI and Big Data AI in Drug Development: Transparency and Risk Assessment” is available here. Enjoy the insightful talk from Dr. Weida Tong (FDA) followed by an interactive Q&A session.

CDDF & Oncology News

Check out the recent updates within the CDDF and the latest news in the community of cancer research

CDDF Brochure

Access the CDDF Brochure here

 

Join the CDDF community—a neutral, multistakeholder platform—to facilitate dialogue, innovate, and accelerate access to the best cancer treatments for all patients.

COLLABORATION IS THE KEY

TO IMPROVING OUTCOMES

FOR CANCER PATIENTS

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

Privacy Policy

info@cddf.org
Tel: +32 2 880 62 70